Use of nonhuman primate models to develop mucosal AIDS vaccines

Meritxell Genescà, Chris J Miller

Research output: Contribution to journalArticle

13 Citations (Scopus)

Abstract

The HIV vaccines tested in the halted Step efficacy trial and the modestly successful phase 3 RV144 trial were designed to elicit strong systemic immune responses; therefore, strategies to direct immune responses into mucosal sites should be tested in an effort to improve AIDS vaccine efficacy. However, as increased CD4 + T-cell activation and recruitment to mucosal sites have the potential to enhance HIV transmission, mucosal immune responses to HIV vaccines should primarily consist of effector CD8 + T cells and plasma cells. Controlling the level of mucosal T-cell activation may be a critical factor in developing an effective mucosal AIDS vaccine. Immunization routes and adjuvants that can boost antiviral immunity in mucosal surfaces offer a reasonable opportunity to improve AIDS vaccine efficacy. Nonhuman primate models offer the best system for preclinical evaluation of these approaches.

Original languageEnglish (US)
Pages (from-to)19-27
Number of pages9
JournalCurrent HIV/AIDS Reports
Volume7
Issue number1
DOIs
StatePublished - Feb 2010

Fingerprint

AIDS Vaccines
Primates
Mucosal Immunity
T-Lymphocytes
Plasma Cells
Antiviral Agents
Immunization
HIV

Keywords

  • Female genital tract
  • HIV
  • Immune activation
  • SIV

ASJC Scopus subject areas

  • Virology
  • Infectious Diseases

Cite this

Use of nonhuman primate models to develop mucosal AIDS vaccines. / Genescà, Meritxell; Miller, Chris J.

In: Current HIV/AIDS Reports, Vol. 7, No. 1, 02.2010, p. 19-27.

Research output: Contribution to journalArticle

@article{4f4f9f2bd9164ff095e63f6acb1a416f,
title = "Use of nonhuman primate models to develop mucosal AIDS vaccines",
abstract = "The HIV vaccines tested in the halted Step efficacy trial and the modestly successful phase 3 RV144 trial were designed to elicit strong systemic immune responses; therefore, strategies to direct immune responses into mucosal sites should be tested in an effort to improve AIDS vaccine efficacy. However, as increased CD4 + T-cell activation and recruitment to mucosal sites have the potential to enhance HIV transmission, mucosal immune responses to HIV vaccines should primarily consist of effector CD8 + T cells and plasma cells. Controlling the level of mucosal T-cell activation may be a critical factor in developing an effective mucosal AIDS vaccine. Immunization routes and adjuvants that can boost antiviral immunity in mucosal surfaces offer a reasonable opportunity to improve AIDS vaccine efficacy. Nonhuman primate models offer the best system for preclinical evaluation of these approaches.",
keywords = "Female genital tract, HIV, Immune activation, SIV",
author = "Meritxell Genesc{\`a} and Miller, {Chris J}",
year = "2010",
month = "2",
doi = "10.1007/s11904-009-0035-7",
language = "English (US)",
volume = "7",
pages = "19--27",
journal = "Current HIV/AIDS Reports",
issn = "1548-3568",
publisher = "Current Science, Inc.",
number = "1",

}

TY - JOUR

T1 - Use of nonhuman primate models to develop mucosal AIDS vaccines

AU - Genescà, Meritxell

AU - Miller, Chris J

PY - 2010/2

Y1 - 2010/2

N2 - The HIV vaccines tested in the halted Step efficacy trial and the modestly successful phase 3 RV144 trial were designed to elicit strong systemic immune responses; therefore, strategies to direct immune responses into mucosal sites should be tested in an effort to improve AIDS vaccine efficacy. However, as increased CD4 + T-cell activation and recruitment to mucosal sites have the potential to enhance HIV transmission, mucosal immune responses to HIV vaccines should primarily consist of effector CD8 + T cells and plasma cells. Controlling the level of mucosal T-cell activation may be a critical factor in developing an effective mucosal AIDS vaccine. Immunization routes and adjuvants that can boost antiviral immunity in mucosal surfaces offer a reasonable opportunity to improve AIDS vaccine efficacy. Nonhuman primate models offer the best system for preclinical evaluation of these approaches.

AB - The HIV vaccines tested in the halted Step efficacy trial and the modestly successful phase 3 RV144 trial were designed to elicit strong systemic immune responses; therefore, strategies to direct immune responses into mucosal sites should be tested in an effort to improve AIDS vaccine efficacy. However, as increased CD4 + T-cell activation and recruitment to mucosal sites have the potential to enhance HIV transmission, mucosal immune responses to HIV vaccines should primarily consist of effector CD8 + T cells and plasma cells. Controlling the level of mucosal T-cell activation may be a critical factor in developing an effective mucosal AIDS vaccine. Immunization routes and adjuvants that can boost antiviral immunity in mucosal surfaces offer a reasonable opportunity to improve AIDS vaccine efficacy. Nonhuman primate models offer the best system for preclinical evaluation of these approaches.

KW - Female genital tract

KW - HIV

KW - Immune activation

KW - SIV

UR - http://www.scopus.com/inward/record.url?scp=77249173172&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77249173172&partnerID=8YFLogxK

U2 - 10.1007/s11904-009-0035-7

DO - 10.1007/s11904-009-0035-7

M3 - Article

C2 - 20425054

AN - SCOPUS:77249173172

VL - 7

SP - 19

EP - 27

JO - Current HIV/AIDS Reports

JF - Current HIV/AIDS Reports

SN - 1548-3568

IS - 1

ER -